Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy

About this update from Urogen Pharma Ltd.

[{"type":"text","content":"PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that adult patients living with recurrent low-grade intermediate-risk non–muscle invasive bladder cancer (LG-IR-NMIBC) now have improved access to an important therapy, as the permanent Healthcare Common Procedure Coding System Level II J Code for ZUSDURI™ (mitomycin) for intravesical solution became effective on January 1, 2026. The new code, J9282, assigned by the Centers for Medicare & Medicaid Services, is expected to streamline billing and reimbursement processes across hospital outpatient and physician office settings, reducing administrative delays that often stand between patients and timely treatment. “Bladder cancer patients repeatedly share with us that delays in access to treatment, not just the disease itself, can be one of the most stressful parts of their care journey,” said Liz Barrett, President and Chief Executive Officer of UroGen. “With the permanent J Code now in effect for ZUSDURI, providers have a clearer, more efficient path to securing reimbursement, which in turn facilitates patient access to ZUSDURI without unnecessary administrative hurdles. This is a meaningful step toward more reliable, predictable access to an important therapy for those navigating this highly recurrent disease.” For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first and only FDA-approved therapy for adults with recurrent LG-IR-NMIBC, offers patients a nonsurgical chemoablative option. “A permanent J Code may seem like a technical change, but for patients, it translates into more broad access to treatment,” said Meri-Margaret Deoudes, CEO of the Bladder Cancer Advocacy Network (BCAN). “Streamlined billing helps treatment centers provide timely care, reduces financial uncertainty, and reduces administrative burden. We applaud the implementation of J9282 and the positive impact we anticipate it will have on the bladder cancer community.” As of January 1, 2026, physicians and treatment centers can utilize J9282 for ZUSDURI when submitting claims for eligible Medicare p...

More updates from Urogen Pharma Ltd.